PSA Cancer Research Results

PSA, prostate-specific antigen: Click to Expand ⟱
Source:
Type:
Prostate-Specific Antigen (PSA) is a protein produced by both normal and malignant cells of the prostate gland. PSA testing is commonly used as a screening tool for prostate cancer.
Elevated levels of PSA in the blood can indicate the presence of prostate cancer, but they can also be caused by other conditions, such as benign prostatic hyperplasia (BPH) or prostatitis (inflammation of the prostate).

PSA is a clinical biomarker.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
207- Api,    Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells
- in-vitro, Pca, LNCaP
PSA↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, P21↑, AR↓,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
5597- Bical,    Bicalutamide: clinical pharmacokinetics and metabolism
- Review, Pca, NA
Dose↝, BioAv↑, Half-Life↑, CYP3A4↓, PSA↓,
704- Bor,    Inhibition of the enzymatic activity of prostate-specific antigen by boric acid and 3-nitrophenyl boronic acid
- in-vitro, Pca, NA
PSA↓,
706- Bor,    Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice
- in-vivo, Pca, LNCaP
TumVol↓, IGF-1↓, PSA↓,
4624- Bor,  VitD3,    Boron as a Medicinal Ingredient in Oral Natural Health Products
- Review, Pca, NA
*Half-Life↝, *eff↑, PSA↓, TumVol↓, IGF-1↓, *memory↓, *motorD↓,
145- CA,  CUR,    The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, PC, DU145
AR↓, ARE/EpRE↑, TumCP↓, PSA↓,
2013- CAP,    Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, P53↑, P21↑, BAX↑, PSA↓, AR↓, NF-kB↓, Proteasome↓, TumVol↓, eff∅,
5930- Catechins,    Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention
- Trial, Pca, NA
PSA↓, other↑, Risk↝,
142- CUR,    Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts
- in-vivo, Pca, LNCaP
AR↓, PSA↓,
151- CUR,    Curcumin analogues with high activity for inhibiting human prostate cancer cell growth and androgen receptor activation
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
AR↓, PSA↓, Dose↑,
153- CUR,    Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7 in Vivo
- in-vivo, Pca, C4-2B
PSA↓, TGF-β↓, BMPs↑, TumMeta↓,
120- CUR,    A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation
- Human, Pca, NA
PSA↓, Dose↝,
122- CUR,  isoFl,    Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen
- Human, Pca, LNCaP
PSA↓, AR↓,
2993- EGCG,    Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
TumCG↓, PSA↓, HK2↓, AR↓, Sp1/3/4↓,
4780- Lyco,    Potential inhibitory effect of lycopene on prostate cancer
- Review, Pca, NA
TumCP↓, TumCCA↑, Apoptosis↑, *neuroP↑, *NF-kB↓, *JNK↓, *NRF2↑, *BDNF↑, *Ca+2↝, *antiOx↑, *AntiCan↑, *Inflam↓, *IL1↓, *IL6↓, *IL8↓, *TNF-α↓, NF-kB↓, DNAdam↓, PSA↓, P53↓, cycD1/CCND1↓, NRF2↓, Akt2↓, PPARγ↓,
66- QC,    Emerging impact of quercetin in the treatment of prostate cancer
- Review, Pca, NA
CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓, TumCCA↑, ROS↑, miR-21↓, TumCP↓, selectivity↑, PDGF↓, EGF↓, TNF-α↓, VEGFR2↓, mTOR↓, cMyc↓, MMPs↓, GRP78/BiP↑, CHOP↑,
70- QC,    Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
PSA↓, AR↓, NKX3.1↓, HK2↓,
82- QC,  ATG,    Arctigenin in combination with quercetin synergistically enhances the anti-proliferative effect in prostate cancer cells
- in-vitro, Pca, LNCaP
AR↓, PI3K/Akt↓, miR-21↓, STAT3↓, BAD↓, PRAS40↓, GSK‐3β↓, PSA↓, NKX3.1↑, Bax:Bcl2↑, miR-19b↓, miR-148a↓, AMPKα↓, TumCP↓, chemoPv↑, TumCMig↓,
75- QC,  ENZ,    Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells
- in-vitro, Pca, HEK293 - in-vitro, NA, 22Rv1 - in-vitro, NA, C4-2B
hnRNPA1↓, PSA↓, NKX3.1↓, FKBP5↓, UBE2C↓, AR-FL↓, AR-V7↑, AR↓, eff↑, TumVol↓, BioAv↓,
3033- RosA,    Rosemary (Rosmarinus officinalis) Extract Modulates CHOP/GADD153 to Promote Androgen Receptor Degradation and Decreases Xenograft Tumor Growth
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP - vitro+vivo, NA, NA
ER Stress↑, selectivity↑, AR↓, TumCG↓, TumCCA↑, CHOP↑, PERK↓, GRP78/BiP↑, PSA↓,
2446- SFN,  CAP,    The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor
- in-vitro, Pca, LNCaP
AR↓, Bcl-xL↓, TumCP↓, Glycolysis↓, HK2↓, PKA↓, Hif1a↓, PSA↓, ECAR↓, BioAv↑, BioAv↓, *toxicity↓,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,

Showing Research Papers: 1 to 23 of 23

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 23

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ARE/EpRE↑, 1,   GSH↓, 1,   NRF2↓, 1,   ROS↑, 2,   ROS⇅, 1,  

Mitochondria & Bioenergetics ⓘ

EGF↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 2,   CYP3A4↓, 1,   ECAR↓, 1,   Glycolysis↓, 1,   HK2↓, 3,   PI3K/Akt↓, 1,   PPARγ↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAD↓, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-xL↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp9↑, 1,   DR5↑, 1,   MAPK↓, 1,   Proteasome↓, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

miR-21↓, 2,   other↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   ER Stress↑, 1,   GRP78/BiP↑, 2,   PERK↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,   NKX3.1↓, 2,   NKX3.1↑, 1,   P53↓, 1,   P53↑, 2,   PARP↑, 1,   PARP1↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   P21↑, 3,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

AR-FL↓, 1,   AR-V7↑, 1,   EMT↓, 1,   GSK‐3β↓, 1,   IGF-1↓, 2,   mTOR↓, 1,   PI3K↓, 1,   Shh↓, 1,   STAT3↓, 1,   TumCG↓, 3,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

Akt2↓, 1,   CDK4/6↓, 1,   E-cadherin↑, 1,   hnRNPA1↓, 1,   miR-148a↓, 1,   miR-19b↓, 1,   MMPs↓, 1,   N-cadherin↓, 1,   PDGF↓, 1,   PKA↓, 1,   TGF-β↓, 1,   TumCMig↓, 1,   TumCP↓, 6,   TumMeta↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 2,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 2,   PSA↓, 23,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 13,   FKBP5↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 2,   ChemoSen↑, 2,   Dose↑, 2,   Dose↝, 2,   eff↑, 1,   eff∅, 1,   Half-Life↑, 1,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 13,   BMPs↑, 1,   EGFR↓, 1,   PSA↓, 23,  

Functional Outcomes ⓘ

chemoPv↑, 1,   OS↑, 1,   Pain↓, 1,   PRAS40↓, 1,   Risk↝, 1,   TumVol↓, 4,   UBE2C↓, 1,  
Total Targets: 102

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   NRF2↑, 1,  

Cell Death ⓘ

JNK↓, 1,  

Migration ⓘ

Ca+2↝, 1,  

Immune & Inflammatory Signaling ⓘ

IL1↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   memory↓, 1,   motorD↓, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 19

Scientific Paper Hit Count for: PSA, prostate-specific antigen
6 Curcumin
4 Quercetin
3 Boron
2 Capsaicin
1 Apigenin (mainly Parsley)
1 Astaxanthin
1 Bicalutamide
1 Vitamin D3
1 Carnosic acid
1 Catechins
1 isoflavones
1 EGCG (Epigallocatechin Gallate)
1 Lycopene
1 Arctigenin
1 enzalutamide
1 Rosmarinic acid
1 Sulforaphane (mainly Broccoli)
1 Selenite (Sodium)
1 Radiotherapy/Radiation
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:264  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page